Industrial Ethernet Protocols IPv6 enabling approach

The current Internet Protocol (IPv4) made Ethernet with TCP/IP find application in industrial automation environment via Industrial Ethernet Protocols. The question "Can things go smooth in Internet Protocol next generation (IPv6)?". This paper answers the question by proposing solutions and proofing via simulation using OPNET Modeler simulator that IPv6 introduction in industrial automation environment introduces very small (negligible) delay relative to IPv4. Measured delays include: global Ethernet delay, IP node end-to-end delay and delay variation for 72, 520 and 1500 bytes transported packet size. Results showed that IPv6 introduces very small delay relative to IPv4, the various delays increase with increased packet size and IPv6 can be used in industrial automation environment. &nbsp

IPv6 Applicability in SCADA System Network

     The trend today is to build a secure fault tolerant Internet/Intranet connected distributed SCADA system networks using open and standard software/hardware. This paper made use of advances in Ethernet such as Fast/Gigabit Ethernet, micro-segmentation and full-duplex operation using switches, IPv6 enhanced features and TCP/IP to fulfill the real-time requirements for SCADA system network. OPNET Modeler simulator is used for modeling and simulating the network. The various measured delays showed that IPv6 introduction in such network introduces very small (negligible) delay and shows better performance on applying Quality of Service relative to IPv4. Also it is found that delays increase with increased transported packet size

Impact of the underlying cause and co-morbid conditions on the outcome of hepatic encephalopathy

Background: Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of acute and chronic liver diseases. This study aimed at identifying liver diseases and co-morbidity conditions associated with hepatic encephalopathy (HE) and their impact on patient`s mortality (the outcome).Methods: A hospital-based, prospective study enrolled 76 patients admitted with HE conducted at Ibn Sina specialized gastroenterology hospital, Sudan, from January 2010 to May 2011. Personal data, clinical presentation, underlying liver disease, precipitants, co-morbid conditions and the outcome of HE were obtained from the inpatients’ hospital records.Results: A total of 76 patients were included, 62 males (81.5%) and 14 females (18.5%) aged between 13 and 84 years old. Hepatitis B virus (HBV) was the most common cause of the liver disease (36.8%), followed by HCV (11.8%). Clinically, 53 patients (69%) had impaired level of consciousness. Infection was the most common risk factor for HE (54%) followed by electrolyte disturbance (42%). Overall mortality within one to three weeks following the admission was (50%). The higher percentage of mortality was seen inpatients with late stage autoimmune hepatitis, followed by HCC and in co-morbid conditions like renal impairment (58.8%).Conclusion: HE is associated with a high mortality despite proper management in specialized hospitals. The mortality tends to increase in the presence of comorbid condition.

Treatment of pre-school children under 6 years of age for schistosomiasis: safety, efficacy and acceptability of praziquantel

BackgroundThe World Health Organization (WHO) recommends praziquantel for the control and treatment of schistosomiasis, with no real alternative. Pre-school children are excluded from population treatment programs mainly due to paucity of safety data on this age group.Objectives: This study investigated safety, efficacy and acceptability of praziquantel for the treatment of S. haematobium and S. mansoni infections among pre-school children aged <6years. The study also investigated the burden of schistosomiasis in this age group.Methods: Pre-school children (n=188) from Sudan were included in the study. The children were treated with praziquantel tablets at a single dose of 40 mg/kg body weight. Adverse events were assessed at 24 hours and 7 days later, via questionnaire administration to parents and guardians.Efficacy of treatment was assessed at 1, 3 and 6 months by examining stool and urine samples for schistosome eggs. Acceptability was determined by the number of children spitting or vomiting during administration of the drug.Results: The burden of schistosomiasis among pre-school children aged <6 years was high (31.1%), and this was comparable to that observed among school children-aged 6 years (32%). Praziquantel treatment achieved high cure rates (egg negative) for both S. haematobium and S.mansoni infections when assessed at 1 month after treatment (89.6-92.1%) and remained high for S. haematobium (89.6-100%) up to 6 months. However, cure rate dropped from 90.5% at one month to 58.8% and 69.2% at 3 and 6 months among S. mansoni-treated children.  Praziquantel treatment decreased egg counts considerably with  post-treatment geometric mean egg reductions rates ranging from 96.4% to 99.4% at 1 month. Acceptability of praziquantel treatment was high, only for one child the dose had to be repeated after initial spitting. Treatment resolved haematuria and improved weight of the children. There were no drug-related adverse events in all the treated children duringfollow-up at 24 hours and 7 days.Conclusions: Praziquantel is safe, effective and acceptable among children aged <6 years. Preschool children represent a high risk group for schistosomiasis and should be included in population treatment programs.Keywords:Schistosomiasis,Praziquantel, Safety,Young Children

A health impact assessment of the UK soft drinks industry levy: a comparative risk assessment modelling study

Background In March, 2016, the UK government proposed a tiered levy on sugar-sweetened beverages (SSBs; high, moderate, and no tax for drinks with >8g, 5g to 8g, and <5g sugar per 100ml). We estimate the effect of possible industry responses to the levy on obesity, diabetes, and dental caries. Methods We modelled three possible industry responses: (1) reformulation to reduce sugar concentration, (2) increasing product price, and (3) changing the market share of high-, mid-, and low-sugar drinks. For each response, we defined a better and worse case health scenario. We developed a comparative risk assessment model to estimate the UK health impact of each scenario. Findings The best modelled scenario for health is SSB reformulation, resulting in 144,000 (95% uncertainty interval: 5,100 to 306,700) fewer adults and children with obesity in the UK, 19,000 (6,900 to 32,700) fewer incident cases of diabetes per year, and 269,000 (82,200 to 470,900) fewer decayed, missing, or filled teeth annually. Increasing the price of SSBs and changes to market share to increase the proportion of low-sugar drinks sold would also result in population health benefits, but to a lesser extent. The greatest benefit for obesity and oral health would be among individuals under 18 years, with people over 65 years experiencing the largest absolute decreases in diabetes incidence. Interpretation The health impact of the soft drink levy is dependent on its implementation by industry. There is uncertainty as to how industry will react and in the estimation of health outcomes. Health gains could be maximised by significant product reformulation with additional benefits possible if the levy is passed onto purchasers through raising the price of high- and mid-sugar drinks, and through activities to increase the market share of low-sugar products.RT and AK have previously done work on sugar-sweetened beverage taxes funded by the Union of European Soft Drinks Associations. MR is chair of Sustain and the Children's Food Campaign, which have campaigned for sugar drink taxes in the UK. MR is funded by the British Heart Foundation, grant number 006/PSS/CORE/2016/OXFORD. ADMB and OTM are members of the Faculty of Public Health, which has a position statement supporting sugary drink taxes. ADMB is funded by the Wellcome Trust, grant number 102730/Z/13/Z. OTM is a member of the UK Health Forum, which has also supported a UK sugar drinks tax. OTM is supported by a Wellcome Trust Clinical Doctoral Fellowship. SAJ was the independent Chair of the Department of Health Public Health Responsibility Deal Food Network from 2010 to 2015. SAJ is funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care Oxford. The views expressed are those of the authors and not necessarily those of the National Health Service, National Institute for Health Research, or the Department of Health. PS is funded by the British Heart Foundation, grant number FS/15/34/31656. TB is funded the Health Research Council of New Zealand (16/443). AE declares no competing interests

Magnetic Inversion Approach For Modeling Data Acquired Across Faults: Various Environmental Cases Studies

An effective extension to the particle swarm optimizer scheme has been developed to visualize and modelize robustly magnetic data acquired across vertical or dipping faults. This method can be applied to magnetic data sets that support various investigations, including mining, fault hazards assessment, and hydrocarbon exploration. The inversion algorithm is established depending on the second horizontal derivative technique and the particle swarm optimizer algorithm and was utilized for multi-source models. Herein, the inversion method is applied to three synthetic models (a dipping fault model contaminated without and with different Gaussian noises levels, a dipping fault model affected by regional anomaly, and a multi-source model) and three real datasets from India, Australia, and Egypt, respectively. The output models confirm the inversion approach\u27s accuracy, applicability, and efficacy. Also, the results obtained from the suggested approach have been correlated with those from other methods published in the literature

Introgression of striga resistance into popular Sudanese sorghum varieties using marker assisted selection

Witchweed (Strigaspp.) is one of the most important cereals production constraints globally and is projected to worsen with anticipated climate change. It is especially a devastating parasitic weed in Sub-Saharan Africa and parts of Asia. Integrated management strategies that depend mainly on host plant resistance provide the most effective control mechanism for Striga. We used molecular marker-assisted backcrossing to introgress Striga resistance from a resistant genotype, N13, into agronomically important genetic backgrounds (Tabat, Wad and Ahmed). Backcross populations BC3S3 were generated and genotyped using Simple Sequence Repeat (SSR) and Diversity Arrays Technology (DArT) markers. A total of 17 promising backcross progenies were selected and screened in Striga infested field alongside their parents. The Area Under Striga Progress Curve (AUSPC) showed significant decrease in Striga count (920-7.5) resulting in a 97-189% increase in yield under Striga pressure. Our results demonstrate the practical application of marker assisted selection (MAS) to generate farmer-preferrd Striga resistant lines in Sudan

Impact of the announcement and implementation of the UK Soft Drinks Industry Levy on sugar content, price, product size and number of available soft drinks in the UK, 2015-19: A controlled interrupted time series analysis.

BACKGROUND:Dietary sugar, especially in liquid form, increases risk of dental caries, adiposity, and type 2 diabetes. The United Kingdom Soft Drinks Industry Levy (SDIL) was announced in March 2016 and implemented in April 2018 and charges manufacturers and importers at £0.24 per litre for drinks with over 8 g sugar per 100 mL (high levy category), £0.18 per litre for drinks with 5 to 8 g sugar per 100 mL (low levy category), and no charge for drinks with less than 5 g sugar per 100 mL (no levy category). Fruit juices and milk-based drinks are exempt. We measured the impact of the SDIL on price, product size, number of soft drinks on the marketplace, and the proportion of drinks over the lower levy threshold of 5 g sugar per 100 mL. METHODS AND FINDINGS:We analysed data on a total of 209,637 observations of soft drinks over 85 time points between September 2015 and February 2019, collected from the websites of the leading supermarkets in the UK. The data set was structured as a repeat cross-sectional study. We used controlled interrupted time series to assess the impact of the SDIL on changes in level and slope for the 4 outcome variables. Equivalent models were run for potentially levy-eligible drink categories ('intervention' drinks) and levy-exempt fruit juices and milk-based drinks ('control' drinks). Observed results were compared with counterfactual scenarios based on extrapolation of pre-SDIL trends. We found that in February 2019, the proportion of intervention drinks over the lower levy sugar threshold had fallen by 33.8 percentage points (95% CI: 33.3-34.4, p < 0.001). The price of intervention drinks in the high levy category had risen by £0.075 (£0.037-0.115, p < 0.001) per litre-a 31% pass through rate-whilst prices of intervention drinks in the low levy category and no levy category had fallen and risen by smaller amounts, respectively. Whilst the product size of branded high levy and low levy drinks barely changed after implementation of the SDIL (-7 mL [-23 to 11 mL] and 16 mL [6-27ml], respectively), there were large changes to product size of own-brand drinks with an increase of 172 mL (133-214 mL) for high levy drinks and a decrease of 141 mL (111-170 mL) for low levy drinks. The number of available drinks that were in the high levy category when the SDIL was announced was reduced by 3 (-6 to 12) by the implementation of the SDIL. Equivalent models for control drinks provided little evidence of impact of the SDIL. These results are not sales weighted, so do not give an account of how sugar consumption from drinks may have changed over the time period. CONCLUSIONS:The results suggest that the SDIL incentivised many manufacturers to reduce sugar in soft drinks. Some of the cost of the levy to manufacturers and importers was passed on to consumers as higher prices but not always on targeted drinks. These changes could reduce population exposure to liquid sugars and associated health risks

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

Background: AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary clinical activity in patients with operable oesophagogastric cancer (OGC). Methods: AZD8931 (20 mg, 40 mg or 60 mg bd) was given with Xelox (oxaliplatin + capecitabine) for eight 21-day cycles, continuously or with intermittent schedule (4 days on/3 off every week; 14 days on/7 off, per cycle) in a rolling-six design. Subsequently, patients with OGC were randomised 2:1 to AZD8931 + Xelox at RP2D or Xelox only for two cycles, followed by radical oesophagogastric surgery. Secondary outcomes were safety, complete resection (R0) rate, six-month progression-free survival (PFS) and overall survival. Results: During escalation, four dose-limiting toxicities were observed among 24 patients: skin rash (1) and failure to deliver 100% of Xelox because of treatment-associated grade III-IV adverse events (AEs) (3: diarrhoea and vomiting; vomiting; fatigue). Serious adverse events (SAE) occurred in 15 of 24 (63%) patients. RP2D was 20-mg bd with the 4/3 schedule. In the expansion phase, 2 of 20 (10%) patients in the Xelox + AZD8931 group and 5/10 (50%) patients in the Xelox group had grade III–IV AEs. Six-month PFS was 85% (90% CI: 66%–94%) in Xelox + AZD8931 and 100% in Xelox alone. Seven deaths (35%) occurred with Xelox + AZD8931 and one (10%) with Xelox. R0 rate was 45% (9/20) with Xelox + AZD8931 and 90% (9/10) with Xelox-alone (P = 0.024). Conclusion: Xelox + AZD8931 (20 mg bd 4/3 days) has an acceptable safety profile administered as neoadjuvant therapy in operable patients with OGC. (Trial registration: EudraCT 2011-003169-13, ISRCTN-68093791)